
pharmaceutical composition as defined in claim 21, for use in reducing exacerbation of an underlying or pre-existing respiratory disease wherein RSV infection is a cause of said exacerbation.

31. A process for preparing the compound of formula (I) as defined in claim 1 comprising the step of reacting an intermediate compound of formula (II)




(II)

with a compound of general formula selected from R-R_8, R-C(=O)R_8, R-C(=S)R_8 and R-$S(O)_2R_8$;


wherein -------, X, X_1, X_2, R_1, Y, Y_1, Y_2, m, n, p and R_8 are as defined in claim 1 and wherein R is a leaving group or an activated ester group;

wherein the obtained compound of formula (I) is optionally converted into a salt or prodrug thereof.

32. The process according to claim 31 further comprising the step of preparing the intermediate compound of formula (II) via cyclisation of a precursor compound of formula (III) or formula (IV) as the case may be



or



(III) (IV)

wherein each A is independently CH or N, R_9 is H or C_{1-3}alkyl and R_1 and Y_1 are as defined in claim 25.

33. A compound of formula (II) as defined in claim 31.

34. The compound of formula (II) according to claim 33 in a single stereoisomeric form.

~~35. A compound of formula (III) as defined in claim 32 wherein R_1 is optionally substituted C_{3-8}cycloalkyl, optionally substituted heterocyclyl or optionally substituted aryl and R_9 is H provided that the compound is not 5-(4-tert-butylphenyl)-2-phenacyl-pyrazole-3-carboxylic acid.~~

36. A compound of formula (IV) as defined in claim 32 wherein R_1 is optionally substituted C_{3-8}cycloalkyl, optionally substituted heterocyclyl or optionally substituted aryl and R_9 is H or or C_{1-3}alkyl.